Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Epitech Group S P A has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The case involves 1 distinct examiner and 1 distinct art unit. RAMOS LEWIS, JOSMALEN MILAGROS is the busiest examiner for the portfolio, handling 1 pending office action.
The presence of 1 pending office action suggests a highly specific prosecution focus for the company. By engaging with 1 distinct examiner in 1 distinct art unit, Epitech Group S P A can concentrate its legal arguments on a single technical front. RAMOS LEWIS, JOSMALEN MILAGROS is the sole individual responsible for evaluating the company's current claims. This structure simplifies the management of the 1 pending office action, as there is no need to coordinate between different examiners or art units. The company's progress in the Biotechnology & Pharmaceuticals sector is currently tied to this single examination process.
For a patent practitioner, the 1 distinct art unit provides a stable regulatory environment for the pending matter. Since RAMOS LEWIS, JOSMALEN MILAGROS is the only examiner involved, the company can tailor its responses specifically to her examination style. The 1 pending office action represents the entirety of the company's current active prosecution at the patent office. This focused approach is typical for portfolios in the Biotechnology & Pharmaceuticals field.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAMOS LEWIS, JOSMALEN MILAGROS | 1 | 53.6% | +23.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18736787 | Adelmidrol For Use In Diseases Characterized By Insufficient Agonism Of PPAR-GAMMA Receptor | RAMOS LEWIS, JOSMALEN MILAGROS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18736787 | Adelmidrol For Use In Diseases Characterized By Insufficient Agonism Of PPAR-GAMMA Receptor | RAMOS LEWIS, JOSMALEN MILAGROS | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18736787 | Adelmidrol For Use In Diseases Characterized By Insufficient Agonism Of PPAR-GAMMA Receptor | RAMOS LEWIS, JOSMALEN MILAGROS | 1621 | §103§112 | Non-Final OA | — | Pending | Jun 07, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial